Lab Test

Prothrombin Genotyping for Thrombotic Risk Assessment

Prothrombin Mutation Analysis, Factor II genotyping, Prothrombin 20210 mutation analysis

Test Codes

EPIC: LAB6389, SOFT: GPROG

Instructions

This test is available to outpatients only. For questions, please call 800-551-0488.

Specimen Collection Criteria

Collect: One 10 mL whole blood in Lavender-top EDTA tube. (Minimum: 5.0 mL)

Physician Office/Draw Specimen Preparation

Do not freeze specimens. Maintain whole blood at room temperature (20-26°C or 68-78.8°F) or refrigerated (2-8°C or 36-46°F) prior to transport.

Preparation for Courier Transport

Transport: Whole blood at room temperature (20-26°C or 68-78.8°F) or refrigerated (2-8°C or 36-46°F). (Minimum: 5.0 mL whole blood)

Rejection Criteria

  • Frozen specimens. 
  • Unlabeled tubes. 
  • Specimens collected in heparin (Green-top), clot tubes (Red-top), or SST tubes.
  • This test will only be performed once in a lifetime for a patient.

In-Lab Processing

Do not freeze specimens. Maintain specimen refrigerated (2-8°C or 36-46°F) prior to testing.

Storage

Specimen Stability for Testing:

Whole Blood
Room Temperature (20-26°C or 68-78.8°F): 72 hours
Refrigerated (2-8°C or 36-46°F): 7 days
Frozen (-20°C/-4°F or below): Unacceptable

Specimen Storage in Department Prior to Disposal:

Refrigerated (2-8°C or 36-46°F): 7 days

Extracted DNA may be available for additional testing if clinically indicated. Contact the Molecular Pathology Laboratory for verification.

Laboratory

Royal Oak Clinical Molecular Pathology Laboratory

Performed

Once per week.
Results available in 7-10 business days.

Reference Range

Negative (no mutation).

Test Methodology

InvaderTM technology using Cleavase Enzyme followed by FRET Detection.

Interpretation

The prothrombin 20210 mutation is a G to A substitution in the 3'-UT region of the prothrombin gene. It has been found in 18% of patients with documented family history of venous thrombosis, 6% of unselected patients with a first episode of deep vein thrombosis and in 1% - 2% of healthy control subjects.

Clinical Utility

  • The prothrombin genotyping is a molecular test for detection of the prothrombin gene mutation G20210A, which results in elevated prothrombin levels and increased risk of venous thrombosis (2.8 fold compared to genotypically normal individuals). Increased risk for arterial thrombosis has also been reported.
  • Testing for Prothrombin Mutation is recommended for:
    • Patients with history of recurrent venous thromboembolisms (VTE), patients with VTE at younger age (less than 50 years), unprovoked VTE at any age, VTE at unusual sites (cerebral, mesenteric, portal, hepatic, vena cava).
    • Patients with positive family history of VTE.
    • Women with VTE during pregnancy/post-partum, oral contraceptive, or hormone replacement therapy.
    • Women with unexplained pregnancy loss.
    • Prior to oral contraceptive use or pregnancy in asymptomatic females, first degree relatives of family member with identified mutation.
    • Children with venous or arterial thrombosis and children who are siblings of patients with early symptomatic VTE.
    • Patients with unexplained arterial thrombosis without atherosclerosis or young patients who smoke.

CPT Codes

81240

Contacts

Last Updated

2/13/2020

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.

 

This directory currently reflects information only for specimens collected and/or processed at the
Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.